Showing 41 - 60 of 123 results
Plans to safely manage medical and research waste
ANSTO will make an application to the independent nuclear regulator, ARPANSA, to vary its license for its Interim Waste Store. The original operating license was approved in 2015, enabling the facility to hold what is called a TN-81 cask of intermediate-level radioactive waste that was safely repatriated from France in 2015.
Feathery moa’s fossilised footprints, ancient age revealed
ANSTO scientist, Dr Klaus Wilcken of the Centre for Accelerator Science, used cosmogenic nuclide dating to determine the ages of layered sand and gravel samples, in which seven footprints of the flightless bird, the moa, were found on the South Island in New Zealand in 2019.
Archive
See details of previously published customer updates from our Health products team.
The science of fireworks
There is chemistry at work to help us enjoy the New Year's Eve celebration.
The 2021 ANSTO Australian Synchrotron Stephen Wilkins Medal
ANSTO is seeking nominations for the ANSTO Australian Synchrotron Stephen Wilkins Thesis Medal.
Highlights - Aerosol Sampling
ANSTO has been tracking and publishing data on fine particle pollution from key sites around Australia, and internationally, for more than 20 years.
Nuclear medicine facilities
To enable the production of nuclear medicine, ANSTO operates manufacturing, processing and distribution facilities in Sydney.
Highlights - Energy Materials
Highlights of the Energy Materials Project.
Experts to discuss latest developments in state-of-the-art radiation treatments for cancer which use accelerated particles
Role at ANSTO
New target developed to improve production of important medical radioisotope
ANSTO has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99 (Mo-99), with less enrichment of uranium-235 (U-235) and produce less waste.
Nuclear technique improves properties of innovative bone implant material
A long-standing collaboration led biomedical researchers from the University of Sydney has recently achieved success with the recent announcement of an innovative bone implant that significantly reduces rejection and inflammation.
Mo-99 Manufacturing Facility
ANSTO's Mo-99 manufacturing facility secures Australia’s ability to produce Mo-99 to meet current and future domestic demand and provide a significant proportion to support global demand.
A bright future for nuclear medicine in Australia
The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.
Understanding how a common food additive causes changes in the microbiome
ANSTO has collaborated on a study assessing the impact of the commonly-used food additive titanium dioxide (TiO2) on gut microbiota and inflammation.
Role at ANSTO
User Meeting 2020 Invited Speakers
The User Advisory Committee (UAC) are pleased to present this year's invited speakers.
Top students selected to work with Australia's best Nuclear Scientists
This month ANSTO is opening its doors to 11 talented young people from across Australia as the two-year Graduate Program kickstarts.